Inclusion Criteria
Articles were included if they met the following criteria: (1)
prospective phase I-III randomized/nonrandomized or single-arm
intervention studies conducted in patients diagnosed with GC or GEJC via
pathology or cytology regardless of HER2 status; (2) studies including
at least one arm treated with HER2-targeted ADC as a single agent; and
(3) studies reporting at least one of the following outcomes:
progression-free survival (PFS); overall survival (OS); objective
response rate (ORR); disease control rate (DCR) and incidence of adverse
events (AEs).